Global Imaging Agents Industry

LONDON, Feb. 9, 2017 /PRNewswire/ -- This report analyzes the worldwide markets for Imaging Agents in US$ by the following Product Segments: Contrast Media (X-Ray/CT, MRI, & Ultrasound), and Diagnostic Radiopharmaceuticals. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa, and Latin America. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 53 companies including many key and niche players such as -

Aytu BioScience, Inc.
Bayer Healthcare Pharmaceuticals
Bracco Diagnostics, Inc.
Daiichi Sankyo Company Limited
Eisai Co., Ltd.

Download the full report: https://www.reportbuyer.com/product/326398/

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1 Disclaimers.............. I-2 Data Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-3 Product Definitions and Scope of Study I-3 A. Contrast Media..............I-3 X-Ray/CT Contrast Media..............I-3 Magnetic Resonance Imaging (MRI) Contrast Media I-3 Ultrasound Contrast Media..............I-4 B. Diagnostic Radiopharmaceuticals I-4

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW.............. II-1 Imaging Agents: A Quick Primer II-1 Market Outlook.............. II-1 Current and Future Analysis..............II-3 Analysis by Region.............. II-3 United States: Holds the Largest Share II-3 Developing Countries: Potentially Lucrative Market II-4 Analysis by Segment..............II-5 Contrast Media: Giving Way to Contemporary Offshoots II-5 Diagnostic Radiopharmaceuticals to Outdo Contrast Media II-6 Nuclear Medicine: A Potential Growth Avenue for Dx Radiopharmaceuticals..............II-7 Select PET and SPECT Radioisotopes Used in Nuclear Medicine II-7 Select Cardiology and Oncology Radiopharmaceuticals II-7 Major Growth Drivers in a Gist II-7 Select Market Growth Restraints..............II-8

2. SEGMENTAL OVERVIEW AND COMPETITIVE LANDSCAPE II-10 Market Structure.............. II-10 Key Market Participants..............II-10 Contrast Media.............. II-11 Popular Brands of Contrast Agents II-11 X-ray Contrast Media..............II-12 Table 1: Annual Sales of Select Key Iodinated Contrast Agents: 2014 & 2015 (In US$ Million) (includes corresponding Graph/Chart).............. II-12 MRI Contrast Media.............. II-12 Market Scenario.............. II-12 Key Players in the MRI Market..............II-13 List of FDA Approved Gadolinium-Based Contrast Agents (GBCA) for CNS MRI..............II-13 List of EMA Approved Gd Chelated Contrast Agents II-14 Controversies over GBCAs Refuse to Die Down II-14 A Comparison of Approved Gadolinium-based Contrast Agents II-15 Select GBCA-Induced Toxicities II-15 Regulators Spring into Action II-16 European Medicines Agency's NSF Risk-based Classification of GBCAs.............. II-16 Competitive Re-arrangement Surfaces as Safety Concerns on GBCAs Reach their Peak..............II-17 Table 2: Annual Sales of Select Key Gadolinium-Based Contrast Agents: 2014 & 2015 (In US$ Million) (includes corresponding Graph/Chart) II-17 Glucose - Can it Replace GBCAs? II-18 Ultrasound Contrast Media..............II-18 Limited System Use Curtails Demand for Ultrasound Contrast Agents; Potential for Further Growth Exists II-18 CEUS and Ultrasound Contrast Agents - A Dichotomy in Approach in Europe and the US II-19 A Comparison of Major Approved UCAs II-20 Approved Ultrasound Contrast Agents by Country and Application II-21 Contrast Media API Production - Still Largely In-house II-22 A Peek into API Supplier Space for Select Contrast Media II-23 Diagnostic Radiopharmaceuticals..............II-24 Market Overview.............. II-24 Commonly Used Diagnostic Radiopharmaceutical Agents II-24 Major Isotopes and their Diagnostic Applications II-25 Select FDA Approved Diagnostic Radiopharmaceuticals by Indication.............. II-26 New Imaging Agent for Radiopharmaceutical Scans II-27 Prospects for Radiopharmaceutical Agents in PET and SPECT Appear Brighter.............. II-27

3. MARKET TRENDS & ISSUES..............II-29 Expansion of Molecular Imaging Platform is Key to Future Growth II-29 Growing Interest in Image Guided Surgery Offers New Opportunities II-29 Fluorescence Optical Imaging - Opens New Avenues II-29 Coronary CT Angiography Opens Up Opportunities for Contrast Agents.............. II-30 List of Iodine-Containing Contrast Agents for Coronary CT Angiography.............. II-30 Targeted Imaging - A Game Changer in the Making? II-30 Clinical Acceptance of MRI Systems on Rise II-31 Nanomaterials Taking the Center Stage II-32 New Nanoparticle Contrast Agents on the Horizon Show Promise II-32 Gadolinium Coated Nanoparticles - A Promising Imaging Agent II-33 Growing Focus on Development of Gold Nanoparticles in X-Ray Imaging.............. II-34 Imaging Agents Make a Welcome Impact in the Field of Alzheimer's Disease..............II-34 List of FDA Approved Alzheimer's Diagnostic Imaging Agents II-35 Contrast-Enhanced Tomosynthesis Expands Opportunities II-35 Hyperpolarized Gases as Contrast Agents II-36 Multi-Modal Imaging: Combating Contrast Medium Inconsistencies II-36 Falling Prices Turn on the Heat II-36 Ultrasound Contrast Agents in Diagnosis of Kidney Ailments II-37 FDA Mandates Black Box Warning Label for Gadolinium-Based MRI Contrast Agents.............. II-37 PET: A Prime Growth Driver for Diagnostic Radiopharmaceuticals II-37 Innovative Radiotracers to Boost Cardiac Applications for SPECT and PET Modalities..............II-38 Global CVD Stats.............. II-39 Table 3: Global Annual Medical Cost of CVD in US$ Billion (2010-2030) (includes corresponding Graph/Chart) II-39

Table 4: Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others (includes corresponding Graph/Chart).............. II-40 Opportunities on Rise for Fluorine-Based Myocardial Perfusion Agents.............. II-40 Unfounded Fears of Radiation Exposure: A Major Concern for Nuclear Diagnostics..............II-41 Rising Incidence of Cancer - A Major Growth Driver II-41 World Cancer Statistics - Incidence and Mortality Data II-41 Table 5: World Cancer Incidence by Geographic Region (2012): Number of New Cancer Cases Reported in Thousands for Asia-Oceania, Europe, North America, Latin America & the Caribbean, and Africa (includes corresponding Graph/Chart).............. II-41

Table 6: World Cancer Mortality by Geographic Region and Gender (2012): Number of Cancer-Related Deaths in Thousands for Asia-Oceania, Europe, North America, Latin America & the Caribbean, and Africa (includes corresponding Graph/Chart).............. II-42 Improving Healthcare Expenditure to Foster Growth II-42 Table 7: Healthcare Spending as % of GDP by Region (2016E) ( includes corresponding Graph/Chart) II-43 Table 8: Healthcare Spending as a Percentage of GDP in Select Countries (2013) (includes corresponding Graph/Chart) II-44

Table 9: Per-Capita Healthcare Spending in Select Countries (2013) (includes corresponding Graph/Chart) II-44 Ageing Population - A Vital Demography II-45 Table 10: Percentage Growth of 65+ Population in North America, Europe, Asia, and Latin America (includes corresponding Graph/Chart)..............II-45

Table 11: Global Population Statistics for the 65+ Age Group (2015) (includes corresponding Graph/Chart) II-46

Table 12: Comparison of Aging Population by Country (1980, 2015 & 2050): Percentage Share of Population Aged Above-65 Years of the Overall Population for Select Countries (includes corresponding Graph/Chart) II-47

Table 13: Life Expectancy for Select Countries in Number of Years: 2015E (includes corresponding Graph/Chart) II-48 A Peek into Pricing Dynamics..............II-48 A Synoptic Overview..............II-48 Pros & Cons.............. II-49 Positive Factors Driving Prices II-49 Negative Factors Bearing Down on Prices II-49 Reimbursements.............. II-50 Europe.............. II-50 United States.............. II-50

4. GLOBAL MEDICAL IMAGING MARKET - AN OVERVIEW II-51 Medical Imaging - Changing the Landscape of Clinical Diagnosis II-51 Table 14: Global Imaging Equipment Market by Modality (2015): Percentage Breakdown of Value for CT, MRI, Nuclear, Ultrasound and X-Ray (includes corresponding Graph/Chart) II-51

Table 15: Global Imaging Equipment Market by Geographic Region (2015): Percentage Breakdown of Value for China, Europe, Japan, North America and Rest of World (includes corresponding Graph/Chart)..............II-52

Table 16: Global Medical Imaging Equipment Installed Base (2013): Percentage Share Breakdown of Volume Installations for X-ray, Ultrasound, Magnetic Resonance, Computed Tomography, and Nuclear Medicine/PET by Country/Region (includes corresponding Graph/Chart) II-52 Comparison of Modalities by Various Imaging Systems II-53 Archaic X-Ray Imaging Modalities Paving Way for Digital X-Rays II-53 Ultrasound Holds its Fort in the Medical Imaging Market II-53 Table 17: World Ultrasound Market by Application (2015): Percentage Breakdown of Usage for Cardiology, Radiology and Others (includes corresponding Graph/Chart) II-54 Technological Advancements Favor MRI Market II-54 Table 18: Global MRI Usage by Application Area (2013) (includes corresponding Graph/Chart) II-56 Comparison of MRI against Other Imaging Modalities II-56 Nuclear Medicine Imaging Equipment Presents Lucrative Growth Opportunities.............. II-56 Table 19: Worldwide Installed Base of Nuclear Imaging Devices by Modality (2013) Percentage Share Breakdown of Number of Installations for SPECT and PET (includes corresponding Graph/Chart).............. II-57 Hybrid Imaging to Herald a New Era of Diagnosis II-57 Hybrid PET/MRI Systems: A New Fusion II-58 Price Sensitivity & Competition from Alternatives Limit Market Potential.............. II-59 Unfounded Fears of Radiation Exposure Hinder Growth II-59 Bottlenecks in Developing Markets II-59 Use of Contrast Agents in Other Imaging Modalities II-60 Fluoroscopy.............. II-60 Computed Tomography..............II-60

5. PRODUCT OVERVIEW.............. II-61 Contrast Agents.............. II-61 Contrast Media: How Do They Function? II-61 Where Are They Used ?..............II-62 Evolution of Contrast Media: A Profile II-62 Bismuth Nitrate: Beginning of Contrast Agents II-62 Imaging Agents: Significant Developments in the Last Fifty Years II-63 Schering Develops First Intravenous Contrast Agent II-63 MRI: Creating a New Era for Contrast Agents II-63 A Peek into the Finer Points of Differences Among Contrast Media II-63 Second Generation Non-Ionic Contrast Agents: An Introduction II-64 Choice of the Contrast Medium: A Weighty Decision II-64 Factors Affecting choice of Imaging Agents II-64 Taxonomy.............. II-64 Types of Contrast Media..............II-65 X-Ray Contrast Medium..............II-65 First Generation High Osmolar Contrast Media II-66 Second Generation Low Osmolar Contrast Media or LOCM II-66 Table 20: Comparative Analysis of Structure of Non-ionic and ionic X-ray Contrast Media II-66 MRI Contrast Medium..............II-66 Role of Contrast Enhancement in MR Angiography (MRA) II-67 MRI Contrast Agents for the Liver II-67 Paramagnetic Extracellular Contrast Agents II-68 Hepatobiliary Gadolinium Chelates II-68 Superparamagnetic Iron Oxide Particles II-68 Ultrasound Contrast Medium..............II-68 Ultrasonographic Contrast Media: What Are They? II-69 Ultrasound Contrast Enhancement in Cardiology II-69 Functionalities of Vascular Ultrasound Contrast Agents II-70 Diagnostic Radiopharmaceuticals II-70 A Delineate of Diagnostic Radiopharmaceuticals II-71 Diagnostic Radiopharmaceuticals: A Technical Run-Through II-71 Applications.............. II-71 Classification.............. II-72 Cardiology Diagnostics..............II-72 Non-cardiology Diagnostics..............II-72 Molecular Imaging Modalities in Radiopharmaceutical Diagnostics.............. II-72 Planar Imaging.............. II-72 Positron Emission Tomography (PET) II-73 Applications of PET..............II-73 Commonly used Radioisotopes in PET Scans II-74 Major PET Isotopes and their Applications II-74 Single Photon Emission Computed Tomography (SPECT) II-75 Applications of SPECT..............II-75 Commonly used Radioisotopes in SPECT Scans II-75

6. TECHNOLOGY DYNAMICS..............II-76 Proprietary Technologies Making In-Roads II-76 Advanced Magnetics' Proprietary Colloidal Superparamagnetic Particle Technology..............II-76 Enzon's Single Chain Antigen-Binding Technology II-76 Immunomedics' Antibody Technology II-76 First Generation..............II-76 Second Generation.............. II-76 Third Generation..............II-76 NeoRx's "Painting the Target" Technology II-77 Stage - I.............. II-77 Stage - II.............. II-77 Stage - III.............. II-77 Gas Encapsulation Technology for Ultrasound Contrast Media II-77 Pharmacyclics' Texaphyrin Technology II-78 Regulatory Bodies.............. II-78 Entry Barriers.............. II-78 Research Driven Markets..............II-78 Highly Competitive Market..............II-78 Economies of Scale.............. II-79 Substitutes in Agents Manufacturing II-79 New X-ray Diagnostic Agents..............II-79 Amide-based Macrocyclic Ligands - Potential MRI Agents II-79 Gadolinium (III) Complexes - Potential MRI Contrast Agents II-79 Metal-Containing Compounds Act As Potential Contrast Agents II-79 Therapeutic Applications..............II-79 Diagnostic Applications..............II-79 Magnetic Gels as Potential MRI Contrast Agents II-80 PFCs as Diagnostic Contrast Agents II-80 Saline Flushes To Help Ensure Accurate Delivery of Contrast Agents.............. II-80

7. PRODUCT LAUNCHES/APPROVALS/ CLINICAL TRIALS II-81 Lantheus Begins Shipment of Xenon Xe 133 Gas II-81 Otsuka Launches ORALTAG™ in the US II-81 Advanced Accelerator Applications Receives FDA Approval for Netspot.............. II-81 Blue Earth Diagnostics Secures FDA Approval for Axumin™ II-81 Bayer Obtains FDA Approval for Gadavist® for MRA for Supra- aortic Arteries.............. II-81 Bracco Secures FDA Clearance for LUMASON in Ultrasonography of the Liver for Lesion Characterization II-82 Bracco Obtains FDA Clearance for READI-CAT® 2 and READI-CAT® 2 SMOOTHIE NDA.............. II-82 Bracco Bags FDA Approval for E-Z-HD for GI Tract Radiohraphic Exams.............. II-82 Bracco Imaging Rolls Out EmpowerCTA®+ Contrast Injection System II-82 Bayer Obtains Label Extension for Gadovist® in the EU II-82 Bayer Receives Approval for Gadovist® for Use with MRI in Japan II-82 Bayer Secures FDA Approval for Gadavist® for Use in Infants II-83 Bracco Makes ISOVUE® Available for POC Use in CT Suite II-83 Bracco Bags FDA Clearance for Lumason™ for Suboptimal Echocardiograms in Adults..............II-83 GE Introduces Vizamyl Alzheimer's Imaging Agent II-83 Navidea Biopharmaceuticals Obtains FDA Approval for Lymphoseek Injection for New Indication..............II-83 Bayer Obtain FDA Approval for Gadavist for Breast Cancer Evaluation.............. II-83 GE Healthcare Gets Norwegian Medicines Agency Approval for Sonazoid™ to Detect Focal Liver Lesions II-84 ImaginAb Announces Initial Phase I/IIa Results for 89Zr-Df- IAB2M Prostate Imaging Agent..............II-84 Piramal Imaging Receives FDA Approval for Neuraceq PET Imaging Agent.............. II-84 NanoHybrids Introduces Premium Product Line of Imaging Contrast Agents.............. II-84 CMC Contrast AB Obtains Orphan Drug Designation from the US FDA for CMC-001.............. II-84 GE Healthcare Obtains FDA Approval for its Oslo Plant to Manufacture Optison Heart Imaging Agent II-85 GE Healthcare Gets FDA Approval for Vizamyl Alzheimer's Imaging Agent.............. II-85 GeccoDots Launches New Contrast Agent II-85 Navidea Biopharmaceuticals Signs Agreement with Nordion II-85 Navidea Biopharmaceuticals Launches Lymphoseek® II-85 GE Healthcare Gets Expanded FDA Approval for AdreView II-85 Guerbet Obtains FDA Approval for Dotarem MRI Contrast Agent II-86 PerkinElmer Introduces GFR-Vivo 680 II-86 Navidea Obtains FDA Approval for Lymphoseek® Injection II-86 Navidea Signs Agreement with Maimonides Medical Center to Collaborate on Clinical Trial Utilizing Lymphoseek® Injection in Colorectal Cancer..............II-86

8. RECENT INDUSTRY ACTIVITY..............II-87 Cell>Point Inks Licensing Agreement with UEP for Oncardia II-87 FluoroPharma Inks Agreement to Take Over Ground Fluor Pharmaceuticals.............. II-87 Bracco Diagnostics's LUMASON® Obtains Innovative Technology Designation from Vizient..............II-87 Blue Earth Diagnostics Establishes Operations in the US II-87 Ipsen and 3B Pharmaceuticals Ink Licensing Deal for Oncology Radiopharmaceuticals..............II-87 Lantheus Divests Gludef® Business in Canada to Isologic II-87 Guerbet Acquires Mallinckrodt's Contrast Media and Delivery Systems Business.............. II-88 Bracco Obtains CMS Pass-Through Status for its Lumason® Ultrasound Contrast Agent..............II-88 Guerbet Inks Deal with Beijing Kyuan Pharmaceutical for Lipiodol® Ultra-Fluid..............II-88 Bracco Expands Group Purchasing Agreement with Amerinet to Include Lumason.............. II-88 Guerbet Inks Agreement with Fuji Pharma to Distribute Contrast Media in Japan.............. II-88 Bayer Inks Agreement with Polysan to Produce Contrast Media in Russia.............. II-88 Blue Earth Diagnostics' Fluciclovine (18F) Obtains Orphan Drug Designation for Glioma Diagnosis in US and Europe II-88 Aytu BioScience Acquires ProstaScint from Jazz Pharmaceuticals II-89 PETNET Solutions Inks Agreement with Blue Earth Diagnostics for Fluciclovine Manufacture and Distribution II-89 Ipsen to Acquire OctreoPharm Sciences II-89 IBA Molecular to Divest US Operations to Illinois Health and Science.............. II-89 Lantheus Obtains sNDA from FDA for Manufacturing NEUROLITE® at Jubilant HollisterStier..............II-89 Lantheus Inks Supply Agreement for Xenon 133 with IRE II-89 AAA to Acquire GE's Italian FDG-PET Imaging Agent Business II-90 ImaginAb Establishes Subsidiary in Japan II-90 ImaginAb and Duke-NUS Partner to Develop in vivo Molecular Imaging Agents.............. II-90 AC Immune and Piramal Imaging Strike Deal to Develop Alzheimer's Imaging Agent..............II-90 Blue Earth Diagnostics Commences Operations II-90 Enlyton Bags SBIR Contract from NCI for Pre-Clinical Development of Tumor Imaging Agent II-90 Guerbet Obtains FDA Approval for Lipiodol Contrast Agent Manufacturing Plant..............II-91 Integrated Diagnostics Launches InDi Molecular II-91 Endocyte Signs Licensing Agreement with Endocyte for etarfolatide Cancer Diagnostic Imaging Agent II-91 Siemens' PETNET Solutions Signs Agreement with Navidea Biopharmaceuticals.............. II-91 Eli Lilly to Acquire two Alzheimer's Imaging Agents from Siemens II-91 Siemens PETNET Solutions Expands Manufacturing and Distribution of Amyvid..............II-91

9. FOCUS ON SELECT PLAYERS..............II-92 Aytu BioScience, Inc. (US)..............II-92 Bayer Healthcare Pharmaceuticals (Germany) II-92 Bracco Diagnostics, Inc. (US)..............II-93 Daiichi Sankyo Company Limited (Japan) II-94 Eisai Co., Ltd. (Japan)..............II-94 Eli Lilly and Company (US)..............II-94 GE Healthcare (UK)..............II-95 Guerbet Group (France)..............II-95 Lantheus Medical Imaging, Inc. (US) II-96 Mallinckrodt plc (Ireland)..............II-97

10. GLOBAL MARKET PERSPECTIVE..............II-98 Table 21: World Recent Past, Current & Future Analysis for Imaging Agents by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) II-98

Table 22: World Historic Review for Imaging Agents by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............II-99

Table 23: World 14-Year Perspective for Imaging Agents by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) II-100

Table 24: World Recent Past, Current & Future Analysis for Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) II-101

Table 25: World Historic Review for Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............II-102

Table 26: World 14-Year Perspective for Contrast Media by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) II-103

Table 27: World Recent Past, Current & Future Analysis for Contrast Media by Product Segment - X-Ray/CT, MRI and Ultrasound Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............II-104

Table 28: World Historic Review for Contrast Media by Product Segment - X-Ray/CT, MRI and Ultrasound Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) II-105

Table 29: World 14-Year Perspective for Contrast Media by Product Segment - Percentage Breakdown of Dollar Sales for X-Ray/CT, MRI and Ultrasound Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) II-106

Table 30: World Recent Past, Current & Future Analysis for X-Ray/CT Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) II-107

Table 31: World Historic Review for X-ray/CT Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............II-108

Table 32: World 14-Year Perspective for X-Ray/CT Contrast Media by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) II-109

Table 33: World Recent Past, Current & Future Analysis for MRI Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) II-110

Table 34: World Historic Review for MRI Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............II-111

Table 35: World 14-Year Perspective for MRI Contrast Media by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) II-112

Table 36: World Recent Past, Current & Future Analysis for Ultrasound Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) II-113

Table 37: World Historic Review for Ultrasound Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............II-114

Table 38: World 14-Year Perspective for Ultrasound Contrast Media by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) II-115

Table 39: World Recent Past, Current & Future Analysis for Diagnostic Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) II-116

Table 40: World Historic Review for Diagnostic Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) II-117

Table 41: World 14-Year Perspective for Diagnostic Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East & Africa and Latin America Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)..............II-118

III. MARKET

1. THE UNITED STATES.............. III-1 A.Market Analysis.............. III-1 Contrast Media Market to Witness Slow but Steady Growth III-1 Table 42: US Contrast Media Market by Leading Players (2013): Percentage Dollar Share Breakdown for Bayer, Bracco, GE Healthcare, Mallinckrodt and Others (includes corresponding Graph/Chart)..............III-2 Diagnostic Radiopharmaceuticals to Drive Future Growth III-2 Table 43: US Nuclear Imaging Market (2015): Percentage Share Breakdown of Procedure Volume for SPECT and PET (includes corresponding Graph/Chart) III-3

Table 44: US Market for Diagnostic Radiopharmaceuticals Agents (2015E): Percentage Share Breakdown of Value Sales for Cardiology and Non-Cardiology Applications (includes corresponding Graph/Chart)..............III-3 Growth Stimulants in a Nut Shell III-3 Demographic Changes Offer Growth Opportunities III-4 Table 45: North American Aging Population by Age Group: 1975-2050 (includes corresponding Graph/Chart) III-4 Dynamics of Pricing..............III-5 Key Trends and Issues..............III-5 Expanding Applications to Stimulate Growth in Dx Radiopharmaceuticals Market..............III-5 New Oncology, Neurology Agents to Boost Growth III-5 Managing Alzheimer's Opens New Avenues for Imaging Agents III-6 List of FDA Approved Alzheimer's Diagnostic Imaging Agents III-7 Alzheimer's Stats..............III-8 Table 46: Alzheimer's Prevalence in the US (2015): As a Percentage of Population by Age-Group (includes corresponding Graph/Chart)..............III-8

Table 47: Alzheimer's Prevalence in the US by State: 2016 & 2025 (includes corresponding Graph/Chart) III-9 Nuclear Cardiology Products Drive Diagnostic Radiopharmaceuticals Market..............III-9 Cardiovascular Imaging to Lead Volume Growth III-10 PET Procedures in the US on Rise III-10 Table 48: US PET Market by Leading Players (2013): Percentage Market Share Breakdown of Value Sales for GE Healthcare, Philips Healthcare, Siemens Healthcare and Others (includes corresponding Graph/Chart) III-11 Growing Adoption of SPECT/CT..............III-11 Rising Incidence of Cancer - A Major Growth Driver III-11 Table 49: New Cancer Cases by Gender and Affected Site in the US (2015) (includes corresponding Graph/Chart) III-12 Isotope Shortage Leads to Dependence on Imports III-13 Shortage of Medical Isotopes Looms Large III-13 Table 50: Nuclear Reactors Producing 99Mo: Potential Annual Output and Estimated Year of Ceasing Production (includes corresponding Graph/Chart) III-14

Table 51: National Programs for New Molybdenum 99 Capacity: Annual Production Estimates and Current Status III-15 DOE's Flawed Isotope Program Adds to the Woe III-15 US Fluorodeoxyglucose (FDG) Market: An Overview III-15 Table 52: US FDG Market by Procedure Type (2012): Percentage Share Breakdown of Procedure Volume for Oncology, Neurology, and Cardiology (includes corresponding Graph/Chart) III-16 Competitive Analysis - Imaging Market III-16 Regulatory Environment..............III-16 Provisions Regarding Off-Label Usage of Contrast Media III-17 Reimbursement Issues..............III-17 Contrast Agents and Diagnostic Radiopharmaceuticals Bundled As Supplies..............III-18 Table 53: CT Reimbursement Changes: CPT Codes for CT and CT Angiography and Payment Rates for 2015 and 2016 III-19

Table 54: MRI Reimbursement Changes: CPT Codes for MRI and MR Angiography (MRA) and Payment Rates for 2015 and 2016.............. III-20 Product Launches/Approvals..............III-21 Strategic Corporate Developments III-25 Key Players.............. III-28 B.Market Analytics..............III-30 Table 55: US Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-30

Table 56: US Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) III-31

Table 57: US 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-32

2. CANADA.............. III-33 A.Market Analysis.............. III-33 Current and Future Analysis..............III-33 An Overview of Medical Imaging Market III-33 Table 58: Percentage Distribution of Canadian Population by Age Group: 2015 (includes corresponding Graph/Chart) III-33 Canadian Scientists Discover Remedy for Isotope Shortages III-33 Regulatory and Legal Restrictions III-34 Strategic Corporate Developments III-34 B.Market Analytics..............III-35 Table 59: Canadian Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-35

Table 60: Canadian Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-36

Table 61: Canadian 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-37

3. JAPAN.............. III-38 A.Market Analysis.............. III-38 Current and Future Analysis..............III-38 Demographics Drive Market Growth III-38 Table 62: Japanese Population by Age Group (2015) (includes corresponding Graph/Chart) III-39

Table 63: Japanese 65+ Years Population: 1950-2010 (includes corresponding Graph/Chart) III-39 Number of Nuclear Medicine Procedures on the Rise III-39 Reimbursement Issues..............III-40 Product Approval..............III-40 Strategic Corporate Developments III-40 Key Players.............. III-41 B.Market Analytics..............III-42 Table 64: Japanese Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-42

Table 65: Japanese Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-43

Table 66: Japanese 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-44

4. EUROPE.............. III-45 A.Market Analysis.............. III-45 Outlook.............. III-45 Nuclear Medicine Imaging Equipment Market: An Overview III-45 Table 67: European Installed Base for Diagnostic Imaging Equipment by Modality (2013): Percentage Share Breakdown of Volume Installations for SPECT, PET/CT, SPECT/CT, Planar, Cardiac SPECT, and PET/MR (includes corresponding Graph/Chart).............. III-46 Cancer: A Major Driver for Diagnostic Radiopharmaceuticals III-46 Table 68: Cancer Incidence in Europe by Site: 2012 (in Thousands) (includes corresponding Graph/Chart) III-47 Ageing Demography - An Opportunity Indicator III-47 Table 69: Population Breakup by Age Group for EU-28 Countries: 2015 (as a Percentage of Total Population) (includes corresponding Graph/Chart) III-48 Reimbursement.............. III-49 Outsourcing of Imaging Diagnostics III-49 Distribution Structure..............III-49 Direct Sales.............. III-49 License Agreements..............III-49 Distribution Agreements..............III-50 A Price Sensitive Market..............III-50 Macro Environment.............. III-50 Germany.............. III-50 France.............. III-50 Spain & Italy.............. III-50 Scandinavia.............. III-51 Product Approval..............III-51 B.Market Analytics..............III-52 Table 70: European Recent Past, Current & Future Analysis for Imaging Agents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-52

Table 71: European Historic Review for Imaging Agents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) III-53

Table 72: European 14-Year Perspective for Imaging Agents by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).............. III-54

Table 73: European Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-55

Table 74: European Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-56

Table 75: European 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-57

4a. FRANCE.............. III-58 A.Market Analysis.............. III-58 Current and Future Analysis..............III-58 Growth Stimulants.............. III-58 Strategic Corporate Developments III-58 Guerbet Group - A Key Player III-59 B.Market Analytics..............III-60 Table 76: French Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-60

Table 77: French Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-61

Table 78: French 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-62

4b. GERMANY.............. III-63 A.Market Analysis.............. III-63 Current and Future Analysis..............III-63 Strategic Corporate Development III-63 Bayer Healthcare Pharmaceuticals - A Key Player III-63 B.Market Analytics..............III-65 Table 79: German Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-65

Table 80: German Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-66

Table 81: German 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-67

4c. ITALY.............. III-68 A.Market Analysis.............. III-68 Current and Future Analysis..............III-68 Strategic Corporate Development III-68 B.Market Analytics..............III-69 Table 82: Italian Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-69

Table 83: Italian Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-70

Table 84: Italian 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-71

4d. THE UNITED KINGDOM..............III-72 A.Market Analysis.............. III-72 Current and Future Analysis..............III-72 Strategic Corporate Development III-72 GE Healthcare - A Major UK-Based Player III-72 B.Market Analytics..............III-73 Table 85: UK Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-73

Table 86: UK Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/ CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart) III-74

Table 87: UK 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-75

4e. SPAIN.............. III-76 Market Analysis.............. III-76 Table 88: Spanish Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-76

Table 89: Spanish Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-77

Table 90: Spanish 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-78

4f. RUSSIA.............. III-79 A.Market Analysis.............. III-79 Current and Future Analysis..............III-79 Strategic Corporate Development III-79 B.Market Analytics..............III-80 Table 91: Russian Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-80

Table 92: Russian Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-81

Table 93: Russian 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-82

4g. REST OF EUROPE.............. III-83 A.Market Analysis.............. III-83 Current and Future Analysis..............III-83 Product Approvals.............. III-83 Strategic Corporate Developments III-84 Mallinckrodt plc - A Major Irish Manufacturer of Nuclear Imaging Agents.............. III-84 B.Market Analytics..............III-85 Table 94: Rest of Europe Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-85

Table 95: Rest of Europe Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-86

Table 96: Rest of Europe 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-87

5. ASIA-PACIFIC.............. III-88 A.Market Analysis.............. III-88 Current and Future Analysis..............III-88 Healthcare Spending in Asia-Pacific: On the Rise III-88 Aging Populace - Potential Opportunities III-89 Table 97: Over 65 Years Individuals as % of Total Population in Select Asian Countries: 2015 (includes corresponding Graph/Chart)..............III-89 India & China Offer Significant Growth Opportunities III-89 MRI Market in Asia..............III-90 B.Market Analytics..............III-91 Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Imaging Agents by Geographic Region - China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-91

Table 99: Asia-Pacific Historic Review for Imaging Agents by Geographic Region - China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-92

Table 100: Asia-Pacific 14-Year Perspective for Imaging Agents by Geographic Region - Percentage Breakdown of Dollar Sales for China, India and Rest of Asia-Pacific Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-93

Table 101: Asia-Pacific Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-94

Table 102: Asia-Pacific Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-95

Table 103: Asia-Pacific 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-96

5a. CHINA.............. III-97 A.Market Analysis.............. III-97 Current and Future Analysis..............III-97 Medical Imaging Equipment Market - An Overview III-97 Increasing Expenditure on Healthcare Sector III-97 Competitive Scenario..............III-98 Table 104: Leading Players in the Chinese CT Contrast Agents Market (2015): Percentage Breakdown of Value Sales for Select Agents (includes corresponding Graph/Chart) III-98

Table 105: Leading Players in the Chinese MRI Contrast Agents Market (2015): Percentage Breakdown of Value Sales for Select Agents (includes corresponding Graph/Chart) III-99 Strategic Corporate Developments III-99 B.Market Analytics..............III-100 Table 106: Chinese Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-100

Table 107: Chinese Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-101

Table 108: Chinese 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-102

5b. INDIA.............. III-103 A.Market Analysis.............. III-103 India - A High Potential Market III-103 Regulatory Mechanism for Guiding Isotope Production and Distribution.............. III-103 Overview of CT Scanners Market in India III-103 PET/CT Scanning in India Gathers Momentum III-104 J.B.Chemicals and Pharmaceuticals Ltd - A Key Player III-104 B.Market Analytics..............III-105 Table 109: Indian Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-105

Table 110: Indian Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-106

Table 111: Indian 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-107

5c. REST OF ASIA-PACIFIC..............III-108 A.Market Analysis.............. III-108 Current and Future Analysis..............III-108 Korea.............. III-108 Strategic Corporate Development III-108 B.Market Analytics..............III-109 Table 112: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/ CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-109

Table 113: Rest of Asia-Pacific Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-110

Table 114: Rest of Asia-Pacific 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-111

6. THE MIDDLE EAST & AFRICA..............III-112 Market Analysis.............. III-112 Table 115: Middle East & African Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/ CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-112

Table 116: Middle East & African Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-113

Table 117: Middle East & African 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-114

7. LATIN AMERICA.............. III-115 A.Market Analysis.............. III-115 Current and Future Analysis..............III-115 Private Sector Boosts Healthcare Segment III-115 B.Market Analytics..............III-116 Table 118: Latin American Recent Past, Current & Future Analysis for Imaging Agents by Geographic Region - Brazil and Rest of Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-116

Table 119: Latin American Historic Review for Imaging Agents by Geographic Region - Brazil and Rest of Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-117

Table 120: Latin American 14-Year Perspective for Imaging Agents by Geographic Region - Percentage Breakdown of Dollar Sales for Brazil and Rest of Latin American Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-118

Table 121: Latin American Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-119

Table 122: Latin American Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-120

Table 123: Latin American 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-121

7a. BRAZIL.............. III-122 Market Analysis.............. III-122 Table 124: Brazilian Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-122

Table 125: Brazilian Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-123

Table 126: Brazilian 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-124

7b. REST OF LATIN AMERICA..............III-125 Market Analysis.............. III-125 Table 127: Rest of Latin America Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart) III-125

Table 128: Rest of Latin America Historic Review for Imaging Agents by Product Segment - Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-126

Table 129: Rest of Latin America 14-Year Perspective for Imaging Agents by Product Segment - Percentage Breakdown of Dollar Sales for Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-127

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 53 (including Divisions/Subsidiaries - 61)

The United States (33) Canada (2) Japan (1) Europe (19) - France (3) - Germany (5) - The United Kingdom (2) - Italy (2) - Rest of Europe (7) Asia-Pacific (Excluding Japan) (5) Africa (1)

Download the full report: https://www.reportbuyer.com/product/326398/

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-imaging-agents-industry-300405338.html

SOURCE ReportBuyer